Literature DB >> 23355654

Implementation of standardized assessment and reporting of myocardial infarction in contemporary randomized controlled trials: a systematic review.

Sergio Leonardi1, Paul W Armstrong, Phillip J Schulte, E Magnus Ohman, L Kristin Newby.   

Abstract

Myocardial infarction (MI) is a key endpoint in randomized controlled trials (RCTs), but heterogeneous definitions limit comparisons across RCTs or meta-analyses. The 2000 European Society of Cardiology/American College of Cardiology MI redefinition and the 2007 universal MI definition consensus documents made recommendations to address this issue. In cardiovascular randomized trials, we evaluated the impact of implementation of three key recommendations from these reports-troponin use to define MI; separate reporting of spontaneous and procedure-related MI; and infarct size reporting. We searched ClinicalTrials.gov and MEDLINE databases for cardiovascular RCTs with more than 500 patients in which enrolment began between September 2000 and July 2012 and that listed MI in the primary endpoint. We searched English-language publications with primary results or design papers. Of 3222 studies screened, 96 (3.0%) met our criteria. We extracted enrolment start date, number of patients and MI events, follow-up duration, and coronary revascularization rate. Data extraction quality was assessed by duplicated extractions. Of 96 RCTs, 80 had a primary results publication, comprising 608 091 patients and 43 621 endpoint MIs. Myocardial infarction represented 45.3% (95% confidence interval, 40.2-50.4) of events in the primary composite endpoint. Troponin defined MI in 57% (53/93) of trials with an MI definition available. Of these RCTs, three used troponin only if creatine kinase-MB was unavailable, six used troponin to define peri-procedural MI, seven specified the 99th percentile as the MI decision limit, and three reported spontaneous and procedure-related MI separately. None reported biomarker-based infarct size, but five reported MI as multiples of the assay upper limit of normal. Although MI is a major component of cardiovascular RCT primary endpoints, standardized MI reporting and implementation of consensus document recommendations for MI definition are limited. Developing appropriate strategies for uniform implementation is required.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23355654      PMCID: PMC3604645          DOI: 10.1093/eurheartj/eht003

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  105 in total

1.  American College of Cardiology key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes. A report of the American College of Cardiology Task Force on Clinical Data Standards (Acute Coronary Syndromes Writing Committee).

Authors:  C P Cannon; A Battler; R G Brindis; J L Cox; S G Ellis; N R Every; J T Flaherty; R A Harrington; H M Krumholz; M L Simoons; F J Van De Werf; W S Weintraub; K R Mitchell; S L Morrisson; R G Brindis; H V Anderson; D S Cannom; W R Chitwood; J E Cigarroa; R L Collins-Nakai; S G Ellis; R J Gibbons; F L Grover; P A Heidenreich; B K Khandheria; S B Knoebel; H L Krumholz; D J Malenka; D B Mark; C R Mckay; E R Passamani; M J Radford; R N Riner; J B Schwartz; R E Shaw; R J Shemin; D B Van Fossen; E D Verrier; M W Watkins; D R Phoubandith; T Furnelli
Journal:  J Am Coll Cardiol       Date:  2001-12       Impact factor: 24.094

2.  The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration.

Authors:  Alessandro Liberati; Douglas G Altman; Jennifer Tetzlaff; Cynthia Mulrow; Peter C Gøtzsche; John P A Ioannidis; Mike Clarke; P J Devereaux; Jos Kleijnen; David Moher
Journal:  Ann Intern Med       Date:  2009-07-20       Impact factor: 25.391

3.  Randomized, non-inferiority trial of three limus agent-eluting stents with different polymer coatings: the Intracoronary Stenting and Angiographic Results: Test Efficacy of 3 Limus-Eluting Stents (ISAR-TEST-4) Trial.

Authors:  Robert A Byrne; Adnan Kastrati; Sebastian Kufner; Steffen Massberg; K Anette Birkmeier; Karl-Ludwig Laugwitz; Stefanie Schulz; Jürgen Pache; Massimiliano Fusaro; Melchior Seyfarth; Albert Schömig; Julinda Mehilli
Journal:  Eur Heart J       Date:  2009-08-30       Impact factor: 29.983

4.  Prognostic significance of elevated troponin I after percutaneous coronary intervention.

Authors:  Warren J Cantor; L Kristin Newby; Robert H Christenson; Robert H Tuttle; Vic Hasselblad; Paul W Armstrong; David J Moliterno; Robert M Califf; Eric J Topol; E Magnus Ohman
Journal:  J Am Coll Cardiol       Date:  2002-06-05       Impact factor: 24.094

5.  Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial.

Authors:  A Michael Lincoff; John A Bittl; Robert A Harrington; Frederick Feit; Neal S Kleiman; J Daniel Jackman; Ian J Sarembock; David J Cohen; Douglas Spriggs; Ramin Ebrahimi; Gadi Keren; Jeffrey Carr; Eric A Cohen; Amadeo Betriu; Walter Desmet; Dean J Kereiakes; Wolfgang Rutsch; Robert G Wilcox; Pim J de Feyter; Alec Vahanian; Eric J Topol
Journal:  JAMA       Date:  2003-02-19       Impact factor: 56.272

6.  Prognostic significance of periprocedural versus spontaneously occurring myocardial infarction after percutaneous coronary intervention in patients with acute coronary syndromes: an analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial.

Authors:  Abhiram Prasad; Bernard J Gersh; Michel E Bertrand; A Michael Lincoff; Jeffrey W Moses; E Magnus Ohman; Harvey D White; Stuart J Pocock; Brent T McLaurin; David A Cox; Alexandra J Lansky; Roxana Mehran; Gregg W Stone
Journal:  J Am Coll Cardiol       Date:  2009-07-28       Impact factor: 24.094

7.  Ticagrelor versus clopidogrel in patients with acute coronary syndromes.

Authors:  Lars Wallentin; Richard C Becker; Andrzej Budaj; Christopher P Cannon; Håkan Emanuelsson; Claes Held; Jay Horrow; Steen Husted; Stefan James; Hugo Katus; Kenneth W Mahaffey; Benjamin M Scirica; Allan Skene; Philippe Gabriel Steg; Robert F Storey; Robert A Harrington; Anneli Freij; Mona Thorsén
Journal:  N Engl J Med       Date:  2009-08-30       Impact factor: 91.245

8.  Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction 38: an application of the classification system from the universal definition of myocardial infarction.

Authors:  David A Morrow; Stephen D Wiviott; Harvey D White; Jose C Nicolau; Ezio Bramucci; Sabina A Murphy; Marc P Bonaca; Christian T Ruff; Benjamin M Scirica; Carolyn H McCabe; Elliott M Antman; Eugene Braunwald
Journal:  Circulation       Date:  2009-05-18       Impact factor: 29.690

9.  Paclitaxel- versus sirolimus-eluting stents for unprotected left main coronary artery disease.

Authors:  Julinda Mehilli; Adnan Kastrati; Robert A Byrne; Olga Bruskina; Raisuke Iijima; Stefanie Schulz; Jürgen Pache; Melchior Seyfarth; Steffen Massberg; Karl-Ludwig Laugwitz; Josef Dirschinger; Albert Schömig
Journal:  J Am Coll Cardiol       Date:  2009-05-12       Impact factor: 24.094

10.  Early versus delayed, provisional eptifibatide in acute coronary syndromes.

Authors:  Robert P Giugliano; Jennifer A White; Christoph Bode; Paul W Armstrong; Gilles Montalescot; Basil S Lewis; Arnoud van 't Hof; Lisa G Berdan; Kerry L Lee; John T Strony; Steven Hildemann; Enrico Veltri; Frans Van de Werf; Eugene Braunwald; Robert A Harrington; Robert M Califf; L Kristin Newby
Journal:  N Engl J Med       Date:  2009-03-30       Impact factor: 91.245

View more
  4 in total

1.  Use of troponin assay 99th percentile as the decision level for myocardial infarction diagnosis.

Authors:  Akshay Bagai; Karen P Alexander; Jeffrey S Berger; Roxy Senior; Chakkanalil Sajeev; Radoslaw Pracon; Kreton Mavromatis; Jose Luis Lopez-Sendón; Gilbert Gosselin; Ariel Diaz; Gian Perna; Jarozlaw Drozdz; Dennis Humen; Birute Petrauskiene; Asim N Cheema; Denis Phaneuf; Subhash Banerjee; Todd D Miller; Sasko Kedev; Herwig Schuchlenz; Gregg W Stone; Shaun G Goodman; Kenneth W Mahaffey; Allan S Jaffe; Yves D Rosenberg; Sripal Bangalore; L Kristin Newby; David J Maron; Judith S Hochman; Bernard R Chaitman
Journal:  Am Heart J       Date:  2017-06-16       Impact factor: 4.749

2.  Consideration of a new definition of clinically relevant myocardial infarction after coronary revascularization: an expert consensus document from the Society for Cardiovascular Angiography and Interventions (SCAI).

Authors:  Issam D Moussa; Lloyd W Klein; Binita Shah; Roxana Mehran; Michael J Mack; Emmanouil S Brilakis; John P Reilly; Gilbert Zoghbi; Elizabeth Holper; Gregg W Stone
Journal:  J Am Coll Cardiol       Date:  2013-10-22       Impact factor: 24.094

3.  Impact of left ventricular hypertrophy on troponin release during acute myocardial infarction: new insights from a comprehensive translational study.

Authors:  Rodrigo Fernández-Jiménez; Jacobo Silva; Sara Martínez-Martínez; M Dolores López-Maderuelo; Mario Nuno-Ayala; José Manuel García-Ruiz; Ana García-Álvarez; Leticia Fernández-Friera; Tech Gonzalo Pizarro; Jaime García-Prieto; David Sanz-Rosa; Gonzalo López-Martin; Antonio Fernández-Ortiz; Carlos Macaya; Valentin Fuster; Juan Miguel Redondo; Borja Ibanez
Journal:  J Am Heart Assoc       Date:  2015-01-21       Impact factor: 5.501

4.  Validation of days at home as an outcome measure after surgery: a prospective cohort study in Australia.

Authors:  Paul S Myles; Mark A Shulman; Stephane Heritier; Sophie Wallace; David R McIlroy; Stuart McCluskey; Isabella Sillar; Andrew Forbes
Journal:  BMJ Open       Date:  2017-08-18       Impact factor: 2.692

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.